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Schizophrenia polygenic risk predicts general
cognitive deficit but not cognitive decline in
healthy older adults
Adrianna P. Kępińska1, James H. MacCabe 1, Dorina Cadar2, Andrew Steptoe2, Robin M. Murray 1 and
Olesya Ajnakina 2,3
Abstract
There has been a long argument over whether schizophrenia is a neurodegenerative disorder associated with
progressive cognitive impairment. Given high heritability of schizophrenia, ascertaning if genetic susceptibility to
schizophrenia is also associated with cognitive decline in healthy people would support the view that schizophrenia
leads to an accelerated cognitive decline. Using the population representative sample of 6817 adults aged >50 years
from the English Longitudinal Study of Ageing, we investigated associations between the biennial rate of decline in
cognitive ability and the schizophrenia polygenic score (SZ-PGS) during the 10-year follow-up period. SZ-PGS was
calculated based on summary statistics from the Schizophrenia Working Group of the Psychiatric Genomics
Consortium. Cognition was measured sequentially across four time points using verbal memory and semantic fluency
tests. The average baseline verbal memory was 10.4 (SD= 3.4) and semantic fluency was 20.7 (SD= 6.3). One standard
deviation (1-SD) increase in SZ-PGS was associated with lower baseline semantic fluency (β=−0.25, 95%CI=−0.40 to
−0.10, p= 0.002); this association was significant in men (β=−0.36, 95%CI=−0.59 to −0.12, p= 0.003) and in those
who were aged 60–69 years old (β=−0.32, 95%CI=−0.58 to −0.05, p= 0.019). Similarly, 1-SD increase in SZ-PGS was
associated with lower verbal memory score at baseline in men only (β=−0.12, 95%CI=−0.23 to −0.01, p= 0.040).
However, SZ-PGS was not associated with a greater rate of decline in these cognitive domains during the 10-year
follow-up. Our findings highlight that while genetic susceptibility to schizophrenia conveys developmental cognitive
deficit, it is not associated with an ongoing cognitive decline, at least in later life. These results do not support the neo-
Kraepelinian notion of schizophrenia as a genetically determined progressively deteriorating brain disease.
Introduction
The question of whether schizophrenia is a neurode-
generative disorder associated with progressive cognitive
impairment has been debated for over a century. Many
psychiatrists, with support from neuropsychological1,2
and neuroimaging3,4 reports, believe that the course of
schizophrenia is characterised by cognitive decline5,6.
However, prospective longitudinal studies are scarce. A
small decline in cognitive function over a 10-year period
following the onset of schizophrenia was reported7, but
the authors could not be certain whether this was due to
some intrinsic schizophrenia process(es) or resulted
from adverse effects associated with its treatment. There
are some suggestions that schizophrenia-related cogni-
tive decline may be particularly pronounced in later
life8,9. Indeed, an 18-year follow-up study showed that
cognition in individuals with a psychotic disorder
declined on all but 2 tests compared with controls, with
the largest effect among participants who were 50 years
or older10.
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Schizophrenia is highly heritable11, with a polygenic
architecture12. Recent evidence suggests that the poly-
genetic underpinning of schizophrenia overlaps with
general cognitive ability13,14. Family studies also high-
light the presence of cognitive impairments in schizo-
phrenia patients prior to the onset of schizophrenia
symptoms15, and in their unaffected relatives but in more
attenuated forms16. Therefore, one of the possible ways
to test the view that schizophrenia leads to a greater rate
of decline in cognition may be through ascertaining
whether genetic susceptibility to schizophrenia is also
associated with cognitive decline in healthy people using
the polygenic score (PGS) approach. PGS for schizo-
phrenia encompasses multiple common genetic variants
of the small effect associated with the illness that are
scattered across the whole genome17, and as such, it
indexes susceptibility for this disease18. Although several
longitudinal studies have attempted to establish the
effect of the PGS on cognition19–21, they produced mixed
results, possibly due to small samples, restricted
accountability of important confounders, or limited
follow-up time-points with intervals ranging over several
decades when measuring cognitive changes in the gen-
eral population. These inconsistent findings reinforce
uncertainty concerning the origins of cognitive impair-
ment in those with schizophrenia.
Therefore, using a large, phenotypically well-defined
sample of population-representative older adults, we
investigated whether common genetic variants associated
with schizophrenia additively confer a stable deficit in
cognitive ability, measured sequentially across four time
points, or a greater risk of accelerated cognitive decline, or
both, over the 10-year follow-up. Assuming a variation in
cognitive impairment in schizophrenia is a function of the
degree of genetic liability to the disorder, we hypothesised
that polygenic score for schizophrenia would be sig-
nificantly associated with lower cognition at baseline and
a greater rate of decline in cognition during follow-up in
healthy adults. Additionally, given age and gender differ-
ences in cognitive functions and schizophrenia risk22–24,
we also investigated whether the potential relationships of
a polygenic score for schizophrenia with cognition at
baseline and during follow-up in healthy adults differed
by age and gender.
Methods
Sample
We utilised data from the English Longitudinal Study of
Ageing (ELSA), which is an ongoing large, multi-
disciplinary study of a nationally representative sample of
the English population aged ≥50 years. The ELSA study
started in 2002 (wave 1), with participants recruited from
an annual cross-sectional survey that is designed to
monitor the health of the general population. The ELSA
sample was then followed-up every 2 years. For the pre-
sent study, baseline data were obtained from either wave 2
(2004–2005) for the core members who started at wave 1,
or wave 4 for the participants joining the study at wave 4
through the refreshment sample; the included participants
took part in the blood draws during home visits by a
nurse. Follow-up data were ascertained from waves 4
(2009–2010) to wave 8 (2016–2017), which is the latest
wave of data collection. We excluded participants with
diagnosed organic causes of cognitive decline, such as
history of dementia and stroke at baseline as well as those
with a previous diagnosis of schizophrenia. Those ELSA
participants who were included in the study or excluded
from the final cohort did not differ in terms of age at
baseline; however, the former group included participants
with a higher educational attainment, higher accumulated
wealth, lower proportion of people with a long-standing
limiting health condition, depressive symptoms and
smokers compared those respondents who were excluded
for relevant variables in this study (Supplementary
Table 1). Ethical approval for each of the ELSA waves was
granted by the National Research Ethics Service (London




Cognition was measured employing tests for verbal
memory and semantic fluency, which were chosen
because both these cognitive domains are important
predictors of clinically significant cognitive decline in
healthy older adults25. To measure verbal memory,
immediate and delayed verbal memory were assessed
using a word-learning task, which entailed recalling as
many out of 10 common words that were read out to
them as possible immediately and after a short delay
during which they completed other cognitive tests26.
Following the protocol of previous studies27, the results
for immediate and delayed recall were then combined to
give an overall verbal memory variable measured on a
continuum from 0 to 10 with a higher score indicating a
better memory performance. Semantic fluency was mea-
sured with a verbal fluency test, where participants were
asked to think of as many animal names as they could in
1 min. The total number of animal names written by
participants was used as a continuous measure of
semantic fluency; the semantic fluency score was mea-
sured on a continuum from 0 to 20 with a higher score
indicating better performance. Although this task pri-
marily focused on semantic fluency, it combined various
aspects of broader executive function including cognitive
flexibility, processing speed, inhibitory control, and verbal
fluency. As semantic fluency test was not administered at
wave 6, in line with previous work in this area26, there was
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a longer follow-up gap in the assessment of this cognitive
domain from wave 5 (2010–2011) to wave 7 (2014–2015)
(Fig. 1). The distribution of these cognitive domains
across all waves of data collection is provided in Supple-
mentary Table 2.
Covariates
We included an extensive set of covariates encom-
passing different aspects of persons’ health and life, which
have been shown to affect cognitive function of older
English people28. Demographic covariates include gender
(male) and age; to capture non-linear aging effects which
cognition is susceptible to, we also included age2 as a
covariate. Social determinants, such as wealth (poorest,
middle and wealthiest as reference) and educational
attainment29, were also included as covariates. To reflect
the accumulation of resources at older ages, wealth was
measured at baseline by summing wealth from property,
possessions, housing, investments, savings, artwork, jew-
ellery and net of debt30. The wealth variable was further
divided into tertile to represent the groups of individuals
with the high, intermediate and low levels of wealth.
Educational attainment was measured with how many
years of schooling each participant completed31. As
comorbid health conditions can affect cognitive ageing,
we included depressive symptoms and the presence of a
limiting long-standing illness as covariates. The presence
of a limiting long-standing illness was measured with the
participants’ reporting presence of any limiting health
illness (coded as “yes”), or absence of any limiting illnesses
or health conditions (coded as “no”). Depressive symp-
toms were measured with an 8-item version of the Centre
for Epidemiologic Studies Depression Scale32, which has
been found to have comparable psychometric properties
to the full 20-item scale;33 a score ≥4 was used to define
participants with severe depressive symptoms34. Beha-
vioural risk factors included smoking status (current
smoker and non-smoker was a reference). Because the ε4
allele of the apolipoprotein E gene (APOE-ε4) has pre-
viously been associated with cognitive decline in normal
aging35, we adjusted our analyses for APOE-ε4. Con-
sistent with previous research36, APOE-ε4 status was
defined according to the absence (APOE ε2/2, ε2/3 and
ε3/3) or presence (APOE ε2/4, ε3/4 and ε4/4) of APOE-ε4
alleles. Lastly, genetic ancestry (as was measured with
principal components (see below)), was included as cov-
ariates to account for any ancestry differences in genetic
structures that could bias our results37.
Genetic data
Quality control
The genome-wide genotyping was performed at Uni-
versity College London Genomics in 2013-2014 using the
Illumina HumanOmni2.5 BeadChips (HumanOmni2.5-
4v1, HumanOmni2.5-8v1.3). Single-nucleotide poly-
morphism (SNPs) were excluded if they were non-auto-
somal, the minor allele frequency was <0.01%, if more
than 2% of genotype data were missing and if the Hardy-
Weinberg Equilibrium p-value<10−4. Samples were
removed based on call rate (<0.99), suspected non-
European ancestry, sex difference in allelic frequency of
≥0.2, heterozygosity and relatedness. We employed the
principal components analysis37 to identify those indivi-
duals who deviated from European ancestry (i.e., ethnic
outliers). This set of analyses demonstrated the presence
of ancestral admixture in the 65 individuals, who were
Fig. 1 Distribution of the cognitive domains across all waves of data collection for the 6817 ELSA participants included in this study
presented as means and standard deviations. The baseline data were obtained from either wave 2 (2004–2005) for the core members who
started at wave 1, or wave 4 for the participants joining the study at wave 4 through the refreshment sample. Follow-up data were ascertained from
waves 4 (2009–2010) to wave 8 (2016–2017), which is the latest wave of data collection.
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subsequently removed; individuals who self-reported they
were of non-white ethnicity were also removed. Using the
updated sample, we calculated principal component (PCs)
(Supplementary Fig. 1), which then were used to adjust for
possible population stratification in the association
analyses37,38.
Polygenic score (PGS) analyses
PGS for schizophrenia (SZ-PGS) was calculated using
summary statistics from genome-wide association study
(GWAS) conducted by the Schizophrenia Working Group
of the Psychiatric Genomics Consortium (PGC)39.
Schizophrenia-associated SNPs, weighted by their effect
size derived from the PGC, were summed in a continuous
score using PRSice40 following specifications outlined
previously41. As previous research highlighted that PGSs
built from directly genotyped data either had more pre-
dictive power31 or did not differ significantly from PGSs
calculated using imputed data41, we calculated PGSs
based on genotyped data at different p-value cut-offs.
Because PGSs including all available SNPs either explain
the most amount of variation in a trait or are not sig-
nificantly different than PGSs based on different p-value
thresholds41, we utilised PGS that was based on a
threshold of p-value of 1. To aid the interpretability of the
results, SZ-PGS was standardised to a mean of 0 (SD= 1).
Statistical analysis
Association analyses
To assess the relationships of SZ-PGS with the general
cognition and the rate of change in cognitive ability
during the 10-year follow-up, we employed linear mixed
effect models (LMMs) with maximum likelihood estima-
tion42. LMMs have been shown to be useful for the ana-
lysis of longitudinal data with an evitable loss to follow-up
data43. Having considered linear, quadratic and cubic
LMMs, Akaike Information Criterion and Bayesian
Information Criterion44,45 showed that the linear model
was the most appropriate for our analyses. To investigate
whether age influenced the potential relationships
between SZ-PGS and cognitive decline over follow-up, we
stratified our analyses by age groups, which were formed
based on tertiles results (i.e., 50–59 years, 60–69 years and
≥70 years). Given the previously observed gender differ-
ences in cognitive functions22, we additionally performed
sex-stratified analyses. We used a significance level of 0.05
(two-tailed) for all analyses. All analyses were conducted
in STATA release 14 (STATA Corp LP, USA).
Calculate power and predictive accuracy of a polygenic score
To investigate whether SZ-PGS included in the present
study had sufficient power to detect relationships with
cognition at baseline and a greater rate of decline in
cognition during follow-up in healthy adults, we estimated
the power of the calculated SZ-PGS using the Avengeme
package implemented in R18. This showed that SZ-PGS
had sufficient power for the subsequent analyses
(power=1, p= 6.26 × 10−17).
Results
Sample characteristics
The baseline demographic and health characteristics of
the total sample are presented in Table 1. The sample
comprised 6817 individuals with a baseline mean age of
64.3 years old (standard deviation (SD)= 9.3, range=
50–101); 25.3% (n= 1724) of participants were APOE-ε4
carriers, 46.2% (n= 3159) were men, 30.9% (n= 2108)
were unmarried and 32.5% (n= 2154) had a low level of
accumulated wealth. The average baseline memory score
was 10.4 (SD= 3.4) and the executive function score was
20.7 (SD= 6.3).
Table 1 Sample characteristics at baseline.
Baseline sample characteristics Total sample
n= 6817
N (%)/Mean (SD)
Age at baseline (years) 64.6 (9.3)
Age groups
50–59 years 2487 (36.5)
60–69 years 2332 (34.2)




APOE-ε4 present 1724 (25.3)






Educational attainment (years) 13.7 (3.8)
Limited life health condition (any) 2132 (31.3)
Depression diagnosis 735 (13.3)
Cognition
Memory score 10.4 (3.4)
Executive function score 20.7 (6.3)
APOE-ε4 two ε4 alleles of the Apolipoprotein E gene, SD standard deviation.
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Rate of change in cognition over the 10-year follow-up
The rate of decline in cognition over the 10-year fol-
low-up is depicted in Fig. 1. The average biennial rate of
decline in verbal memory during the 10 years was 1.21
points (95%CI= 0.99–1.44, p < 0.001). For semantic
fluency, the average biennial rate of decline was 1.36
points (95%CI= 1.07–1.65, p < 0.001) over the follow-
up period.
SZ-PGS and verbal memory in older adults
There was a trend towards a statistically significant
relationship of one standard deviation (1-SD) increase
in SZ-PGS with a lower baseline verbal memory score
(β=−0.07, 95%CI=−0.14–0.01, p= 0.091) (Table 2).
When the analyses were stratified by gender, the results
showed that 1-SD increase in SZ-PGS was associated with
lower verbal memory score in men (β=−0.12, 95%CI=
−0.23 to −0.01, p= 0.040) but not in women (Supple-
mentary Table 3) highlighting a significant interaction
with gender. There was also a trend towards significance
in the relationship of SZ-PGS with verbal memory score
in older adults who were aged 70 years old and older (β=
−0.14, 95%CI=−0.28–0.004, p= 0.056) (Supplementary
Table 4). Nonetheless, there was no significant association
between SZ-PGS and the rate of decline in verbal memory
during the 10-year follow-up period.
Table 2 Associations between schizophrenia polygenic score (SZ-PGS) and cognitive function in older adults over the
10-year follow-up.
Verbal memory Semantic fluency
β (95%CI) P-value β (95%CI) P-value
Baseline
SZ-PGS −0.07 (−0.14–0.01) 0.091 −0.25 (−0.40 to −0.09) 0.002
Age −0.14 (−0.15 to −0.14) <0.001 −0.19 (−0.21 to −0.18) <0.001
Gender −1.08 (−1.23 to −0.92) <0.001 0.02 (−0.29 to 0.33) 0.906
Current smoker −0.10 (−0.33–0.13) 0.386 −0.58 (−1.04 to −0.12) 0.013
Low level of wealth −0.60 (−0.77 to −0.42) <0.001 −0.62 (−0.97 to −0.27) <0.001
Education attainment 0.19 (0.17–0.21) <0.001 0.43 (0.38 to 0.47) <0.001
Depression diagnosis −0.53 (−0.77 to −0.30) <0.001 −0.81 (−1.28 to −0.33) 0.001
APOE-ε4 present −0.27 (−0.45 to −0.10) 0.002 −0.31 (−0.66 to 0.04) 0.074
Limiting health conditions (any) −0.18 (−0.35 to −0.01) 0.041 −0.17 (−0.66 to 0.04) 0.320
Rate of change
SZ-PGS 0.003 (−0.01–0.02) 0.741 0.01 (−0.02–0.03) 0.740
Age −0.06 (−0.03–−0.09) <0.001 0.06 (0.002–0.11) 0.044
Gender −0.02 (−0.05–0.01) 00.285 −0.06 (−0.12 to −0.002) 0.041
Current smoker −0.07 (−0.12–−0.02) 0.002 −0.05 (−0.14–0.03) 0.229
Low level of wealth −0.01 (−0.04–0.03) 0.707 −0.08 (−0.14 to −0.01) 0.028
Education attainment 0.002 (−0.002–0.01) 0.255 −0.01 (−0.01–0.002) 0.121
Depression diagnosis −0.01 (−0.06–0.04) 0.629 −0.05 (−0.15 to 0.04) 0.258
APOE-ε4 present −0.08 (−0.12–−0.04) <0.001 −0.10 (−0.16 to −0.03) 0.005
Limiting health conditions (any) −0.03 (−0.06–0.01) 0.126 −0.11 (−0.18 to −0.05) 0.001
Variancea
Within-person 0.07 (0.06–0.08) 0.16 (0.13–0.21)
In initial status 3.69 (3.66–4.28) 15.99 (14.77–17.31)
In rate of change 0.03 (−0.02–0.08) 0.08 (−0.09–0.26)
The models were further adjusted for age2 to capture non-linear aging effects of which cognition is susceptible to and 4 principal components to account for any
ancestry differences in genetic structures that could bias the results.
CI confidence intervals, SZ-PGS polygenic score for schizophrenia, APOE-ε4 two ε4 alleles of the Apolipoprotein E gene.
aThe within-person variance is the overall residual variance in cognition that is not explained by the model. The initial status variance component is the variance of
individuals’ intercepts about the intercept of the average person. The rate of change variance component is the variance of individual slopes about the slope of the
average person.
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SZ-PGS and semantic fluency in older adults
1-SD increase in SZ-PGS was associated with lower
sematic fluency at baseline (β=−0.25, 95%CI=
−0.40–0.09, p= 0.002). Further analyses showed this
association was significant in men (β=−0.36, 95%CI=
−0.59 to −0.12, p= 0.003) (Supplementary Table 3) and
in those who were aged 60–69 years old (β=−0.32, 95%
CI=−0.58 to −0.05, p= 0.019) (Supplementary Table 5).
Although APOE-ε4, tobacco smoking, educational
attainment and lower wealth were inversely associated
with semantic fluency during follow-up, SZ-PGS was not
associated with a greater rate of decline in these cognitive
domains during the 10-year follow-up period.
Discussion
In the present study, we investigated the relationships of
multiple common genetic variants for schizophrenia,
which additively indexed susceptibility for this illness18,
with cognition and rate of decline in cognition during
the 10-year follow-up period in a large population-
representative sample of older adults. At the core of the
study was the notion that if cognitive impairment in
schizophrenia is a consequence of genetic liability to the
disorder, with greater impairment indicating greater lia-
bility, the association between the genetic liability to
schizophrenia and cognitive decline would be observed in
non-psychotic adults.
In support of the previous findings highlighting mole-
cular genetic overlap between general cognitive ability and
risk for schizophrenia in the general population13,14, we
found that SZ-PGS was significantly associated with lower
verbal memory and semantic fluency scores at baseline in
men independently from demographic factors, health-
related factors and APOE-ε4 status. This is consistent
with earlier twin studies which highlighted that boys had
higher heritability for a verbal measure of cognitive ability
compared to girls46,47, in turn highlighting that this
genetic propensity to a higher verbal measure of cognitive
ability in men extends to later lifeAdditive contribution of
common genetic markers for schizophrenia was also sig-
nificantly higher for semantic fluency score among adults
who were aged 60–69-year old, supporting the notion
that genetic influence on sematic fluency differs by age
groups48.
In contrast to our hypothesis, however, common genetic
variants associated with schizophrenia additively did not
confer a greater rate of decline in cognition during the 10-
year follow-up in older people from the general popula-
tion. Although some evidence for gender differences in
cognitive aging exist, as further supported by our results,
these were not associated with genetic propensity for
schizophrenia. The fact that we observed a significant
cognitive decline during the follow-up period linked to
the effects of APOE-ε4, tobacco smoking, educational
attainment and lower wealth, demonstrates our study had
the capacity to capture the cognitive decline over time in
community-dwelling older adults. Consequently, our
results contradict McIntosh et al.20 who, having measured
cognitive changes between ages 11 and approximately 70
in a large birth cohort, suggested that common genetic
variants for schizophrenia accelerate cognitive ageing
among non-psychotic individuals. As the timing and tra-
jectory of these changes were unknown, it is possible such
deficits may have arisen during adolescent rather than in
later life49. Indeed, cognitive deficits have been shown to
be present at a young age in some children who later
developed schizophrenia50. The young children who are
destined to develop schizophrenia show slower cognitive
development in a range of cognitive domains, which
results in further divergence in cognitive ability by the
time schizophrenia develops50. However, evidence for the
subsequent long-term cognitive decline during the tran-
sition to schizophrenia or following its onset is lack-
ing51,52. In a subsequent analysis conducted by Ritchie
et al.21 on the same sample as McIntosh et al.20 but
capturing individuals aged 70–79-year old, a significant
inverse relationship of schizophrenia polygenic score with
general cognitive slope was observed. Although this
finding appears to support a genetic overlap between
cognitive decline and schizophrenia, this relationship did
not survive multiple-comparisons correction. Since
Ritchie et al.21 measured general cognition using the
block-design task in contrast to the present verbal
memory tasks, this may be a source of discrepancy
between the studies. Nonetheless, our findings are further
consistent with the results reported by Liebers et al.19 who
found an association between SZ-PGS and cognitive
deficit at age 60 years in 8616 community-dwelling indi-
viduals, but did not find a relationship between SZ-PGS
and cognitive decline over the next decade.
There is growing interest in improving cognitive func-
tions in patients with schizophrenia through pharmaco-
logical treatment or cognitive rehabilitation programmes.
Our findings raise the possibility that the cognitive decline
reported in schizophrenia patients may be due to other
factors rather than intrinsic genetically determined schi-
zophrenia process(es). The causes of cognitive decline in
schizophrenia may include factors secondary to illness-
related behaviours, such as substance abuse, cigarette
smoking, poor nutrition as well as exposure to medica-
tions used in treating the disorder, such as antipsychotics,
anticholinergics, and benzodiazepines49. Antipsychotic
medications may also explain the brain changes, such as
cortical gray matter reductions53, which in turn have been
used as evidence that this illness is a progressive brain
disorder52. Other factors including decreased environ-
mental stimuli related to social isolation might also
play a role in reducing cognitive capacity in patients with
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schizophrenia52. Certainly, there is evidence suggesting
that loneliness contributes to a worsening in memory and
verbal fluency over a decade in the general population26.
Cumulatively, our results do not support the neo-
Kraepelinian notion of schizophrenia as a genetically
determined progressively deteriorating brain disease, at
least at the molecular level. Therefore, it may be impor-
tant for optimum clinical care to reconsider the idea of
the existence of intrinsically malignant process(es)
underlying schizophrenia. This has contributed to an
undue pessimism among mental health professionals and
their consequent alienation from sufferers and their
representatives, who increasingly advocate for the
“recovery model”49. Of course, this is not to negate the
serious and disabling problems that many patients with
schizophrenia experience. Nonetheless, it is still possible
that only a subset of the genetic factors for schizophrenia
drive cognitive decline observed in patients with this ill-
ness, which, due to the nature of the PGS approach, might
not have been captured in the present study. Therefore,
further analyses, such as pathway-specific polygenic score
analyses, genomic structural equation modelling and
gene-set enrichment analyses, may be needed before we
can draw more precise conclusions of the role schizo-
phrenia risk loci may play in general cognition.
Methodological considerations
We analysed a large nationally-representative cohort of
older adults in England who were followed-up every two
years. We further benefitted from the availability of
repeated measures of cognition across a 10-year span. Our
study included a relatively equal proportion of women
and men from socio-economically diverse backgrounds.
Confidence in these findings is strengthened by the use of
a linear mixed model, which is an optimal way to identify
the change in continuous dependent variables over time
and quantify its association with a range of independent
variables, all the while taking the intra-individual and
inter-individual variation into account. To avoid provid-
ing results of questionable theoretical relevance51, we did
not present our results as composite scores for broad
cognitive functions; instead, we explored verbal memory
and semantic fluency separately. The comprehensive
inclusion of covariates in the analyses meant that we
could control for identified confounding variables redu-
cing any potential risk for biases in our results.
Nonetheless, several methodological limitations warrant
a discussion. Although PGSs have the potential to
improve health outcomes through their eventual imple-
mentation as clinical biomarkers, the poor generalisability
of genetic studies across populations is noteworthy54. This
is because the construction of PGSs is largely dependent
on the availability of the summary statistics from genome-
wide association studies (GWASs), which are currently
predominately based on European participants54. Given
genetic risk is different in European and non-European
individuals54, further work is necessary to develop PGSs
models in non-white populations. Similarly, by design,
polygenic scores do not capture other structural variants
beyond common genetic markers of relatively small
effects, such as rare variants, poorly tagged or multiple
independent variants, gen-by-gene interactions and gene-
environment correlation55. Therefore, these factors will
not be accounted for when applying PGSs in the analyses.
Further, the lack of a pre-registered analytical protocol is a
notable limitation of the present study. The presence of
practice effects may have limited the observed decline in
cognitive abilities. However, in line with the previous
evidence56, the potential practice effects may be insignif-
icant given the relatively long interval between the
assessments of cognitive domains (i.e., 2 years). Finally, we
assessed several associations, which may raise some con-
cerns over multiple statistical testing. Considering our
sample size was large enough to withstand multiple test-
ing without increasing risk for false positive results and
the fact that adjusting for multiple statistical testing has
significant disadvantages57, rather than adjusting our
p-values for multiple-testing, we followed the new
guidelines for statistical reporting58 when presenting the
results in the present study.
Conclusion
Our findings highlight that while genetic susceptibility to
schizophrenia conveys developmental cognitive deficit, it is
not associated with an ongoing cognitive decline, at least in
later life. Thus, our results do not provide support for the
neo-Kraepelinian notion of schizophrenia as a genetically
determined progressively deteriorating brain disease.
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